Cognition in Parkinson's disease - Vol II

Cognitive impairment in Parkinson’s disease (PD) represents a growing area of interest within neuroscience and clinical research, given PD's evolution from being defined as a predominantly motor disorder to a recognized multisystem disease. Over recent years, it has become evident that cognitive symptoms, ranging from mild cognitive impairment to overt dementia, are common among individuals with PD and contribute substantially to patient morbidity, caregiver burden, and socioeconomic costs. Understanding the progression and mechanisms of cognitive decline in PD is complicated by its often subtle onset during the prodromal phase and the diverse clinical presentations linked to genetic, environmental, and biological factors. Although advances in neuroimaging, genetics, and neuropathology have enriched our grasp of cognitive dysfunction in PD, significant gaps remain in elucidating the disease’s heterogeneity, the interplay of neurobiological pathways, and the social determinants influencing disease outcomes.Presently, the clinical assessment of cognitive impairment in PD frequently relies on conventional neuropsychological evaluations, with limited integration of digital and data-driven diagnostic innovations in routine practice. Pharmacological therapies for dementia in PD are available, but their therapeutic impact is modest, and there is a striking scarcity of effective prevention strategies and comprehensive care models tailored to cognitive dysfunction. As research begins to address health equity issues within PD populations—highlighted by disparities in access, outcomes, and recognition across socioeconomic, racial, and gender lines—it is increasingly important to broaden both scientific inquiry and intervention paradigms.This Research Topic aims to synthesize the evolving landscape of cognitive dysfunction in PD by fostering multidisciplinary research into its mechanisms, diagnostics, and interventions. It seeks to gather evidence on innovative pharmacological and non-pharmacological therapies, promote the use of digital and AI-assisted assessment tools, and drive the development of PD-specific care strategies that holistically address cognitive needs. Furthermore, the topic intends to illuminate social and health equity dimensions within cognitive decline, offering a nuanced understanding of how diverse backgrounds impact the lived experience and management of PD.The scope of this Research Topic encompasses both basic and clinical research, including the prodromal and manifest stages of PD. Its limitations exclude focus outside cognitive domains and non-PD neurodegenerative conditions. To gather further insights in these boundaries, we welcome articles addressing, but not limited to, the following themes:- Cellular and neurobiological mechanisms underlying cognitive decline in PD- Early-stage clinical diagnostics of cognitive dysfunction, including digital and AI-based approaches- Pharmacological, non-pharmacological, and combined interventions for prevention or mitigation of cognitive symptoms- Care concepts and comprehensive management frameworks for cognitive dysfunction in PD- The impact of health inequalities and sociocultural factors on cognitive outcomes in PD populationsReviews and original research—both quantitative and qualitative—on the prodromal and clinical stages of cognitive impairment in PD are welcomed, with particular encouragement for studies recognizing health inequalities related to socioeconomic status, race, or gender. Topic editors: Wolfgang H. Jost, Elke Kalbe, Prof. Dr. Source: https://www.frontiersin.org/research-topics/80106/cognition-in-parkinsons-disease---vol-ii